Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 3
2005 2
2006 2
2007 2
2008 1
2010 1
2011 3
2012 2
2013 5
2014 1
2015 7
2016 7
2017 7
2018 2
2019 5
2020 7
2021 6
2022 7
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
Mannose 6-phosphate receptor-targeting antibodies preserve Fc receptor-mediated recycling.
Gauthier C, Mariot J, Daurat M, Dhommée C, El Cheikh K, Morère E, Depaepe G, Gary-Bobo M, Morère A, Garcia M, Basile I, Gouilleux-Gruart V, Maynadier M. Gauthier C, et al. Among authors: gouilleux gruart v. J Control Release. 2023 Jun;358:465-475. doi: 10.1016/j.jconrel.2023.05.011. Epub 2023 May 13. J Control Release. 2023. PMID: 37169177
Finding the Right Heavy Chains for Immunostimulatory Antibodies.
Boulard P, Gouilleux-Gruart V, Watier H. Boulard P, et al. Among authors: gouilleux gruart v. Int J Mol Sci. 2022 Sep 8;23(18):10367. doi: 10.3390/ijms231810367. Int J Mol Sci. 2022. PMID: 36142278 Free PMC article. Review.
Anticalin N- or C-Terminal on a Monoclonal Antibody Affects Both Production and In Vitro Functionality.
Aubrey N, Gouilleux-Gruart V, Dhommée C, Mariot J, Boursin F, Albrecht N, Bergua C, Croix C, Gilotin M, Haudebourg E, Horiot C, Matthias L, Mouline C, Lajoie L, Munos A, Ferry G, Viaud-Massuard MC, Thibault G, Velge-Roussel F. Aubrey N, et al. Among authors: gouilleux gruart v. Antibodies (Basel). 2022 Aug 22;11(3):54. doi: 10.3390/antib11030054. Antibodies (Basel). 2022. PMID: 35997348 Free PMC article.
Angiogenic factors could help us to define patients obtaining complete response with undetectable minimal residual disease in untreated CLL patients treated by FCR: results from the CLL2010FMP, a FILO study.
Gagez AL, Paul F, Alaterre E, Gouilleux-Gruart V, Tuaillon E, Lepretre S, Ternant D, Letestu R, Moreaux J, Cartron G. Gagez AL, et al. Among authors: gouilleux gruart v. Leuk Lymphoma. 2021 Dec;62(13):3160-3169. doi: 10.1080/10428194.2021.1955879. Epub 2021 Nov 22. Leuk Lymphoma. 2021. PMID: 34806520
Therapeutic antibodies - natural and pathological barriers and strategies to overcome them.
Al Ojaimi Y, Blin T, Lamamy J, Gracia M, Pitiot A, Denevault-Sabourin C, Joubert N, Pouget JP, Gouilleux-Gruart V, Heuzé-Vourc'h N, Lanznaster D, Poty S, Sécher T. Al Ojaimi Y, et al. Among authors: gouilleux gruart v. Pharmacol Ther. 2022 May;233:108022. doi: 10.1016/j.pharmthera.2021.108022. Epub 2021 Oct 20. Pharmacol Ther. 2022. PMID: 34687769 Free PMC article. Review.
69 results